Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 278

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 1B
Chunk 278
---
 extensions of the deadlines to complete the Business Combination or the Business Combination itself, or any other transactions after January 31, 2025. The business address of such holder is 1200 N Federal Hwy, #200, Boca Raton FL 33432.

(5)This
                                            information is based solely on a Schedule 13G filed by Mizuho Financial Group, Inc. (“Mizuho”)
                                            with the SEC on February 10, 2023. Mizuho has sole voting power of 493,672 shares and sole
                                            dispositive power of 493,672 shares. The number of shares held by Mizuho is reported as of
                                            December 31, 2022, as stated in the Schedule 13G, which does not reflect any redemption of
                                            shares by Mizuho in connection with extensions of the deadlines to complete the Business
                                            Combination or the Business Combination itself, or any other transactions after December
                                            31, 2022. The business address of such holder is 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100-8176,
                                            Japan.

29

As of April 1, 2025, our initial
shareholders beneficially owned approximately 47% of issued and outstanding ordinary shares and have the right to appoint all of our directors
prior to our initial business combination. Holders of our public shares will not have the right to appoint any directors to our board
of directors prior to our initial business combination. Because of this ownership block, our sponsor may be able to effectively influence
the outcome of all other matters requiring approval by our shareholders, including amendments to our amended and restated memorandum and
articles of association and approval of significant corporate transactions including our initial business combination.

Our
sponsor has agreed (a) to vote any founder shares and public shares held by it in favor of any proposed business combination and (b)
not to redeem any founder shares or public shares held by it in connection with a shareholder vote to approve a proposed initial business
combination.

Our
sponsor, our officers, our directors and US Tiger are deemed to be our “promoters” as such term is defined under the federal
securities laws.

Transfers
of Founder Shares and Private Placement Warrants

The
founder shares, Private Placement Units, Private Placement Shares, Private Placement Warrants and any Class A ordinary shares issued
upon conversion or exercise thereof are each subject to transfer restrictions pursuant to lock